2022 American Transplant Congress
Kidney Transplantation Utilizing SARS-CoV-2 Rt-PCR Positive Donor Kidneys with Immediate Post Exposure Casirivimab /Imdevimab Followed by Thymoglobulin Induction
*Purpose: At the beginning of the pandemic, kidneys from SARS-CoV-2 (COVID) RT-PCR positive donors were not utilized for transplantation, due to the risk of viral…2022 American Transplant Congress
Humoral and Cellular Immunity 6 Months After SARS-CoV-2 Infection in Solid-Organ Transplant Recipients
*Purpose: The purpose of this study was to evaluate long term humoral and cellular immunity generated following SARS-CoV-2 infection in solid organ transplant recipients (SOTR).*Methods:…2022 American Transplant Congress
Re-Infection with SARS-CoV-2 in Solid-Organ Transplant Recipients: Incidence Density and Convalescent Immunity Prior to Re-Infection
*Purpose: The purpose of this study was to study our cohort of adult solid organ transplant recipients who had been infected with SARS-CoV-2 to describe…2021 American Transplant Congress
Safety of Sars-cov-2 Mrna Vaccines in Solid Organ Transplant Recipients
Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: The safety of SARS-CoV-2 mRNA vaccines in solid organ transplant recipients (SOTRs) remains unknown. We investigated adverse events in SOTRs who received these mRNA…2021 American Transplant Congress
Living Organ Donor Perspectives on Covid-19 Vaccines
*Purpose: Promoting widespread COVID-19 vaccinations is a crucial strategy to protect living organ donors and transplant recipients during the pandemic. We examined perspectives and sources…2021 American Transplant Congress
Covid-19 Infections Post-liver and Kidney Transplantation in a Southern Ca Program
*Purpose: Southern CA is at the epicenter of the Covid-19 pandemic. We reviewed outcomes of our center's liver, kidney, and pancreas transplant patients stricken with…2021 American Transplant Congress
A Mechanistic Evaluation to Guide the Optimal Immunosuppression Adjustment Strategy in Transplant Patients with COVID-19
*Purpose: The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. Reduction in calcineurin inhibitors or antimetabolite doses is often performed in…2021 American Transplant Congress
Sars-cov-2 Stat Testing for Organ Donation; One Laboratory’s Experience
*Purpose: The COVID-19 pandemic took the U.S. by storm. The Transplant Community had to navigate through unprecedented scenarios in order to continue the life-saving mission…2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…2021 American Transplant Congress
Covid-19 Severity within One Year of Liver, Pancreas and Kidney Transplantation
Solid Organ Transplant Surgery, University of Minnesota, Minneapolis, MN
*Purpose: The current pandemic has created uncertainty in the severity of COVID-19 in transplant recipients, especially those given lymphocyte depleting therapy within a year prior…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- Next Page »